Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia

BACKGROUND: Immune thrombocytopenia (ITP) is an auto-immune disorder characterized by enhanced platelet destruction and, subsequently, the potential for increased bleeding. Thrombopoietin receptor (TPO-R) agonists have recently emerged as promising therapies for ITP patients who are refractory to ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Dolph, Mike, Bhor, Menaka, Said, Qayyim, Roy, Anuja, Elliott, Brian, Briggs, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223346/
https://www.ncbi.nlm.nih.gov/pubmed/30464564
http://dx.doi.org/10.2147/CEOR.S177338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223346/
https://www.ncbi.nlm.nih.gov/pubmed/30464564
http://dx.doi.org/10.2147/CEOR.S177338

Ejemplares similares